NO20032586D0 - Nukleinsyrevaksiner som anvender tumor antigen-kodende nukleinsyrer med cytokin adjuvant-kodende nukleinsyre - Google Patents

Nukleinsyrevaksiner som anvender tumor antigen-kodende nukleinsyrer med cytokin adjuvant-kodende nukleinsyre

Info

Publication number
NO20032586D0
NO20032586D0 NO20032586A NO20032586A NO20032586D0 NO 20032586 D0 NO20032586 D0 NO 20032586D0 NO 20032586 A NO20032586 A NO 20032586A NO 20032586 A NO20032586 A NO 20032586A NO 20032586 D0 NO20032586 D0 NO 20032586D0
Authority
NO
Norway
Prior art keywords
nucleic acid
coding nucleic
tumor antigen
coding
cytokine adjuvant
Prior art date
Application number
NO20032586A
Other languages
English (en)
Other versions
NO20032586L (no
Inventor
Linda Snyder
Bernard Scallon
David M Knight
Stephen G Mccarthy
Theresa J Goletz
Patrick J Branigan
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of NO20032586D0 publication Critical patent/NO20032586D0/no
Publication of NO20032586L publication Critical patent/NO20032586L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20032586A 2001-10-10 2003-06-06 Nukleinsyrevaksiner som anvender tumor antigen-kodende nukleinsyrer med cytokin adjuvant kodende nukleinsyre NO20032586L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32837101P 2001-10-10 2001-10-10
PCT/US2002/029640 WO2003031569A2 (en) 2001-10-10 2002-09-18 Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid

Publications (2)

Publication Number Publication Date
NO20032586D0 true NO20032586D0 (no) 2003-06-06
NO20032586L NO20032586L (no) 2003-08-04

Family

ID=23280723

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032586A NO20032586L (no) 2001-10-10 2003-06-06 Nukleinsyrevaksiner som anvender tumor antigen-kodende nukleinsyrer med cytokin adjuvant kodende nukleinsyre

Country Status (7)

Country Link
US (1) US20050261213A1 (no)
EP (1) EP1507540A4 (no)
AR (1) AR036793A1 (no)
AU (1) AU2002326961A1 (no)
BR (1) BR0206112A (no)
NO (1) NO20032586L (no)
WO (1) WO2003031569A2 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) * 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
ES2345200T3 (es) * 2003-03-24 2010-09-17 The Scripps Research Institute Vacunas de adn contra el crecimiento tumoral y procedimientos de utilizacion de las mismas.
ES2476990T3 (es) * 2003-11-12 2014-07-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sistema para tratar y prevenir cáncer de mama
WO2005046622A2 (en) 2003-11-12 2005-05-26 Therion Biologics Corporation Custom vectors for treating and preventing pancreatic cancer
DK1839120T3 (da) * 2004-12-21 2013-11-11 Janssen Biotech Inc Vektorer baseret på Anti-IL-12-antistoffer, værtsceller og fremgangsmåder til fremstilling og anvendelser
EP1848804B1 (en) 2005-01-28 2011-10-05 Ramot at Tel Aviv University, Ltd. Anti-muc1 alpha beta antibodies
EP3524262A1 (en) * 2013-11-01 2019-08-14 Pfizer Inc Vectors for expression of prostate-associated antigens
US20190125852A1 (en) * 2016-06-03 2019-05-02 Etubics Corporation Compositions and methods for tumor vaccination using prostate cancer-associated antigens
JP7795181B2 (ja) 2017-09-06 2026-01-07 イェール ユニバーシティー インターロイキン－１８バリアントとその利用法
JP7287611B2 (ja) * 2018-02-07 2023-06-06 学校法人日本医科大学 改良型アデノ随伴ウイルスベクター
CN108624691A (zh) * 2018-06-22 2018-10-09 杭州西合精准医疗科技有限公司 一种用于判断前列腺疾病的标志物及其应用
US12029778B2 (en) 2019-05-13 2024-07-09 Yale University Interleukin-18 mimics and methods of use
CA3191540A1 (en) * 2020-09-02 2022-03-10 4D Molecular Therapeutics Inc. Codon optimized rpgrorf 15 genes and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013268A (en) * 1994-04-22 2000-01-11 Corixa Corporation Methods for enhancement of protective immune responses
DE19648625A1 (de) * 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
AU4224599A (en) * 1998-05-29 1999-12-13 Trustees Of The University Of Pennsylvania, The Anti-prostate cancer vaccines, and methods of making, using and evaluating the same
US6387888B1 (en) * 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US6495130B1 (en) * 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
AU2002239441A1 (en) * 2000-11-01 2002-05-27 American Foundation For Biological Research, Inc. Methods and compositions for inducing cell-mediated immune responses

Also Published As

Publication number Publication date
WO2003031569A2 (en) 2003-04-17
WO2003031569A3 (en) 2004-12-29
NO20032586L (no) 2003-08-04
AU2002326961A1 (en) 2003-04-22
AR036793A1 (es) 2004-10-06
BR0206112A (pt) 2005-05-10
EP1507540A4 (en) 2006-12-06
EP1507540A2 (en) 2005-02-23
US20050261213A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
DK1946772T3 (da) Multivalent vaccinesammensætning
EP1385538A4 (en) CHIMERIC VACCINE
FR14C0016I2 (fr) Vacccin west nile
NO20041157L (no) HIV-GAG kodonoptimaliserte DNA-vaksiner
NO20035208D0 (no) Nytt vaksine preparat
CY2016018I1 (el) Εμβολιο κατα του ιου του δυτικου νειλου
PL363005A1 (pl) Szczepionki
NO20034683D0 (no) Intradermal vaksineinnretning
IS7133A (is) Afleiða beta-amyloid - T-frumu-mótefnavísisbóluefni
NO20031274L (no) Anvendelse av immidazokinolinaminer som adjuvanter i DNA- vaksinasjon
ATE534402T1 (de) Multivalente impfstoffzusammensetzung
NO20050132D0 (no) Vaksinesammensetning
ITMI20021135A0 (it) Seggiolone per bambini e simili con mezzi di azionamento facilitato
EP1423141A4 (en) VACCINE
NO20033882L (no) Vaksine
DK1265633T3 (da) Vaccineadjuvans
EP1446129A4 (en) POLYNUCLEOTIDE THERAPY
NO20032586L (no) Nukleinsyrevaksiner som anvender tumor antigen-kodende nukleinsyrer med cytokin adjuvant kodende nukleinsyre
EP1409011A4 (en) PRIME-BOOST IMPF STRATEGY (28.07.01)
DE60328408D1 (de) Impfstoff
DK1923071T3 (da) Equint herpesvirusvaccine
ATE437656T1 (de) Impfstoff gegen das maul- und klauensäure-virus
NO20051561D0 (no) Vaksine
DE10290185D2 (de) Tumorvakzine
NO20011921D0 (no) Sulfidoamidokarboksylsyrer, metoder for fremstilling derav og anvendelser derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application